XCUR Exicure, Inc.
Price Chart
Executive Summary
Exicure received a Nasdaq non-compliance notice for late filing of its Q1 2026 10-Q, but filed the report on May 29, 2026 and believes it has regained compliance. The company is exploring strategic alternatives after restructuring and suspending clinical activities, with a lead program in stem cell mobilization.
Actionable Insight
The late filing issue has been resolved, removing immediate delisting risk. However, the company's ongoing exploration of strategic alternatives suggests potential M&A, asset sale, or reverse merger. Monitor for announcements regarding strategic transactions or further restructuring.
Key Facts
- Nasdaq notified Exicure on May 28, 2026 of non-compliance with Listing Rule 5250(c)(1) due to delayed 10-Q filing.
- The 10-Q for the three months ended March 31, 2026 was filed on May 29, 2026, curing the deficiency.
- Company is exploring strategic alternatives after restructuring and suspension of clinical/development activities.
- Lead program is in stem cell mobilization for multiple myeloma, sickle cell disease, and cell/gene therapy.
Financial Impact
No financial figures disclosed in the press release.
Risk Factors
- Nasdaq could still impose additional listing requirements or penalties despite the cure.
- Strategic alternatives may not result in value realization for shareholders.
- Lead program is early-stage and may not succeed in clinical trials.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304694 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
3d ago
|
Press Release
| $3.11 $3.16 | ▲ +1.61% | ▲ +2.30% | $2.90 (−6.75%) |
|
Jun 1, 2026
4d ago
|
8-K
| $3.33 $3.11 | ▼ −6.61% | ▼ −6.75% | $2.90 (−12.91%) |
|
Apr 10, 2026
7w ago
|
8-K
| $3.85 $3.79 | ▼ −1.56% | ▼ −2.77% | $2.90 (−24.64%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $4.61 $4.42 | ▲ +4.23% | ▲ +2.55% | $2.90 (+37.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access